Australia is a world leader in developing and evaluating prophylactic HPV vaccination. The academic team has made considerable contributions to this research effort, ranging from developing innovative interactive information for adolescents, to biomedical evaluation of safety, tolerability and efficacy.

In 2013 we received $5,986,258 in grant income, published 21 papers and presented at 37 local and international meetings.